AUS
NZ
UK
CA
USA
IND
_06_04_2026_05_16_02_212823.jpg)
Highlights
- Secures multi-million-dollar R&D loan facility
- Advancing world-first Binge Eating Disorder trial
- Exploring wider clinical applications for psilocin therapy
Tryptamine Therapeutics Ltd (ASX:TYP) has expanded its financial capacity through a newly secured multi-million-dollar research and development loan facility. This strategic funding is designed to advance the company’s lead intravenous psilocin program, known as TRP-8803, which targets Binge Eating Disorder (BED).
The loan is structured to be repaid from future R&D Tax Incentive refunds, enabling the Melbourne-based biotech to maintain operational flexibility. The capital will supplement the company’s existing cash reserves, reinforcing its ability to progress its clinical initiatives without altering share capital structures.
Progress in BED Clinical Trial
The company’s landmark BED clinical trial is being conducted in partnership with Swinburne University. Regulatory clearance has been obtained to handle and administer the controlled substance, paving the way for treatment sessions to commence.
The open-label trial will involve a small patient group, with participants receiving two intravenous infusions of TRP-8803 alongside structured psychotherapy. The primary objective is to evaluate safety, while also monitoring therapeutic indicators such as changes in binge-eating patterns and related health markers.
Innovative Approach to Psychedelic-Assisted Therapy
TRP-8803 is a proprietary intravenous psilocin formulation created to address the limitations associated with oral psilocybin, such as unpredictable onset and extended treatment sessions. By offering a more controlled and time-efficient administration, the therapy aims to improve the patient experience and overall treatment practicality.
The development builds on earlier findings from the company’s oral psilocybin formulation, TRP-8802, which demonstrated notable clinical benefits in BED. With encouraging prior results, TRP-8803 is now positioned to potentially extend its applications to other health conditions, including fibromyalgia and irritable bowel syndrome.
For investors and market watchers, while Tryptamine is not currently part of the ASX 200, its advancements in psychedelic-assisted therapy underscore a growing biotech segment that continues to attract research interest.
Frequently Asked Questions
- What is TRP-8803?
TRP-8803 is an intravenous psilocin formulation developed to provide controlled, rapid onset of psychedelic-assisted therapy for conditions such as Binge Eating Disorder. - How will the R&D loan facility support Tryptamine’s goals?
The funding will help accelerate clinical trials and expand research programs without affecting the company’s share structure. - Are there plans for TRP-8803 beyond BED?
Yes, the company is exploring potential applications in conditions like fibromyalgia and irritable bowel syndrome, building on earlier positive results with a related oral formulation.
